An Open-Label, 2-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants With Newly-Diagnosed Multiple Myeloma

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date2/04/23 → 1/04/26

Keywords

  • Clinical Trials
  • Multiple Myeloma